NasdaqGS:TEMLife Sciences
Did Tempus AI's (TEM) Pediatric AML Registry Push into Patient Apps Just Shift Its Investment Narrative?
Earlier this month, Blood Cancer United and Tempus AI announced a collaboration to build a comprehensive, patient-centered real-world registry for pediatric acute myeloid leukemia, using Tempus’ olivia app and Lens analytics platform to unify data, support families, and inform research.
This partnership, alongside new research showing Tempus’ advanced genomic profiling can uncover treatment-relevant findings missed by standard tests, highlights how the company’s AI and data tools are...